New drug applications approved by US FDA as of 01 - 15 June 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
The reduced mortality/morbidity benefit previously demonstrated with selexipag in patients with pulmonary arterial hypertension (PAH) may be more pronounced when treatment is initiated soon after diagnosis, according to results of a post hoc analysis of the GRIPHON* study presented as a poster at ATS 2019.
Diagnosis of gastro-oesophageal reflux disease (GERD) remains unclear in patients with subacute/chronic cough, especially those with low blood eosinophil counts ≤150/μl, but using the Frequency Scale for the Symptoms of GERD (FSSG) questionnaire may considerably help, suggests a study presented at the recent American Thoracic Society (ATS) 2019 International Conference held at Dallas, Texas in the US.
Treatment with dupilumab, a fully human monoclonal antibody that inhibits interleukin (IL)-4 and IL-13 signalling, significantly reduces severe exacerbation rate and improves lung function in patients with late-onset asthma, according to results of a post hoc analysis of the Liberty Asthma Quest* trial presented at ATS 2019.
Extended preloading of varenicline for 6 weeks before the target quit day (TQD) safely improves the efficacy of the prescription medication in facilitating smoking cessation at 12 weeks and at 6 months, according to a study presented at the American Thoracic Society (ATS) 2019 International Conference, held at Dallas, Texas in the US.
Smokers tend to suffer from poor sleep health, reports a new study presented at the recently concluded 2019 International Conference of the American Thoracic Society (ATS 2019). Moreover, having poor sleep health may intensify existing deficits in lung health in these individuals.
Rapid identification of pathogens using a molecular point-of-care testing (POCT) significantly reduces intravenous antibiotic use and the duration of hospitalization among patients with acute lower respiratory tract infection (LRTI), a study presented at ATS 2019 shows.
A 3-month treatment course of low-dose azithromycin for acute exacerbations of chronic obstructive pulmonary disorder appears to safely reduce treatment failure by preventing transfer to intensive care or readmission for respiratory causes, according to a posthoc analysis of the BACE* trial presented at the American Thoracic Society (ATS) 2019 International Conference.
Early neuromuscular blockade (NMB) with concomitant heavy sedation in patients with moderate-to-severe acute respiratory distress syndrome (ARDS) did not result in a significant mortality difference vs usual care, the ROSE* trial has shown.
Treatment with the tyrosine kinase inhibitor (TKI) nintedanib reduces pulmonary function decline in patients with systemic sclerosis–associated interstitial lung disease (SSc-ILD), according to the phase III SENSCIS* trial which is touted as the largest randomized controlled trial in SSc-ILD thus far.
Initial acute respiratory illness (ARI) admissions related to human adenovirus (HAdV), human metapneumovirus (hMPV) and human rhinovirus (HRV) occurring during early infancy increase the risk of subsequent ARI-related readmission, a recent study has shown.
Getting vaccinated against influenza can improve survival of patients with heart failure (HF), with earlier and more frequent vaccination being associated with a greater protection against deaths from cardiovascular (CV) events or any cause, a large Danish nationwide cohort study shows.